Exploration of Novel Biomarkers through a Precision Medicine Approach Using Multi-omics and Brain Organoids in Patients with Atypical Depression and Psychotic Symptoms
Preprint
Abstract
Major depressive disorder (MDD) with atypical features accompanied by psychotic symptoms represents a severe and under-researched subtype of depression and severe mental illness, characterized by significant personal and social impact. This study aims to explore novel biomarkers through a precision medicine approach by integrating clinical data, white blood cell (WBC) single-cell RNA sequencing (scRNA-seq), plasma proteomics, and brain organoid models to uncover immunological and neurological alterations in patients with this condition. Patients exhibited elevated stress, anxiety, and depression levels, with increased WBC counts. Plasma proteomic profiling identified an upregulation of proteins implicated in synaptic formation, including Doublecortin-Like Kinase 3 (DCLK3) and Calcyon (CALY), as well as immune-related proteins such as Complement Component 5 (C5). WBC scRNA-seq revealed significant neutrophil and monocyte transcriptomic alterations, suggesting increased inflammation and immune dysregulation. Patient-derived brain organoids display reduced growth and distinct gene expression patterns compared to controls, particularly under dexamethasone-induced stress conditions. Integrating multi-omics data and brain organoid models offers a novel framework for understanding the pathophysiology of psychiatric disorder, which is one of the most complex disorders.Keywords
All Related Versions
- Published version: Advanced Science, 13 (4), e08383.
This publication has 83 references indexed in Scilit:
- HSPA6 and its role in cancers and other diseasesMolecular Biology Reports, 2022
- Psychotic symptoms in first‐episode and drug naïve patients with major depressive disorder: Prevalence and related clinical factorsDepression and Anxiety, 2020
- Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic DysregulationsJAMA Psychiatry, 2017
- IL-1 receptor 2 (IL-1R2) and its role in immune regulationBrain, Behavior, and Immunity, 2013
- A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant DepressionJAMA Psychiatry, 2013
- Depressive disorders and immunity: 20 years of progress and discoveryBrain, Behavior, and Immunity, 2007
- CALCYONgene variation, schizophrenia, and cocaine dependenceAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2003
- The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic ReviewBrain, Behavior, and Immunity, 2001
- Different immune patterns in melancholic and non-melancholic major depressionEuropean Archives of Psychiatry and Clinical Neuroscience, 2001
- Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosisProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1993